Published in

American Association for Cancer Research, Clinical Cancer Research, 20(20), p. 5147-5149, 2014

DOI: 10.1158/1078-0432.ccr-14-0820

Links

Tools

Export citation

Search in Google Scholar

Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!

Journal article published in 2014 by Maria G. Castro, Gregory J. Baker ORCID, Pedro R. Lowenstein
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Immunosuppressive checkpoints mediated by IDO, CTLA4, and PD1/PDL1 play a critical role in glioma progression and the efficacy of immunotherapies. Combined blockade of these immunosuppressive checkpoints in a glioma model elicited long-term survival. This combined blockade adds to the armamentarium of anti-glioma therapies, which could be implemented in clinical trials. Clin Cancer Res; 20(20); 5147–9. ©2014 AACR.